X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/intensity-therapeutics-provides-business-update-reflecting-progress-in-phase-3-sarcoma-program-302024890.html
https://ir.intensitytherapeutics.com/news-events/press-releases/detail/77/intensity-therapeutics-appoints-joseph-talamo-cpa-as
https://ir.intensitytherapeutics.com/news-events/press-releases/detail/76/intensity-therapeutics-presents-positive-int230-6-data-in
https://ir.intensitytherapeutics.com/news-events/press-releases/detail/75/intensity-therapeutics-selected-for-spotlight-oral
https://www.prnewswire.com/news-releases/intensity-therapeutics-presents-positive-int230-6-data-in-patients-with-refractory-soft-tissue-sarcoma-at-the-connective-tissue-oncology-society-annual-meeting-2023-301974975.html
https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-second-quarter-financial-results-and-provides-corporate-update-301899473.html
https://endpts.com/cancer-biotech-intensity-therapeutics-looks-to-pull-in-16m-ipo/
https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-int230-6-can-cause-immune-priming-in-historically-quiescent-breast-cancers-301841914.html
https://www.prnewswire.com/news-releases/intensity-therapeutics-int230-6-prolongs-survival-alone-or-in-combination-with-ipilimumab-in-adult-patients-with-relapsed-refractory-metastatic-sarcomas-301841753.html
https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-use-of-int230-6-alone-or-in-combination-with-ipilimumab-shows-evidence-of-direct-tumor-necrosis-and-promising-overall-survival-results-in-adult-subjects-with-metastatic-sarcomas-at-the-connective-tis-301682483.html
Market Place
Share 
